GlassScriptPhysician profile
Michael P Riggleman
NPI 1831163500
$4,700.53
in general payments reported to CMS, 2019-2025
29 companies · $630 in 2025
The $630 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $386 · 2021: $265 · 2022: $593 · 2023: $846 · 2024: $745 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $950.15 | 2019-2025 | Farxiga, Airsupra, Bevespi Aerosphere |
| Novo Nordisk INC | $835.76 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $525.66 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $523.23 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $330.89 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $162.80 | 2019-2021 | |
| Saluda Medical Americas, INC. | $158.39 | 2024 | Evoke |
| Exact Sciences Corporation | $139.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $136.32 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Amarin Pharma, INC. | $136.01 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $134.93 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $115.45 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.82 | 2019-2024 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $73.00 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.33 | 2024-2025 | Caplyta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.78 | 2022-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $45.63 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Mylan Specialty L.P. | $41.16 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $35.68 | 2024-2025 | Voquezna |
| Philips North America LLC | $22.06 | 2019 | |
| Eisai INC. | $18.92 | 2024 | |
| Xeris Pharmaceuticals, INC. | $17.93 | 2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $15.33 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.12 | 2019 | |
| Dexcom, INC. | $14.78 | 2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $14.40 | 2025 | Freestyle Libre 3 |
| Vertex Pharmaceuticals Incorporated | $14.21 | 2025 | |
| Alkermes, INC. | $13.68 | 2023 | Aristada, Lybalvi |
| Medtronic, INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Riggleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.